- Home
- MDGL vs BRKR Comparison
MDGL vs BRKR Comparison
Compare MDGL & BRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- BRKR
- Stock Information
- Founded
- MDGL 2011
- BRKR 1960
- Country
- MDGL United States
- BRKR United States
- Employees
- MDGL N/A
- BRKR N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- BRKR Biotechnology: Laboratory Analytical Instruments
- Sector
- MDGL Health Care
- BRKR Industrials
- Exchange
- MDGL Nasdaq
- BRKR Nasdaq
- Market Cap
- MDGL 6.1B
- BRKR 5.3B
- IPO Year
- MDGL N/A
- BRKR 2000
- Fundamental
- Price
- MDGL $440.75
- BRKR $33.27
- Analyst Decision
- MDGL Strong Buy
- BRKR Buy
- Analyst Count
- MDGL 10
- BRKR 11
- Target Price
- MDGL $474.67
- BRKR $50.00
- AVG Volume (30 Days)
- MDGL 341.0K
- BRKR 4.7M
- Earning Date
- MDGL 10-30-2025
- BRKR 11-04-2025
- Dividend Yield
- MDGL N/A
- BRKR 0.60%
- EPS Growth
- MDGL N/A
- BRKR N/A
- EPS
- MDGL N/A
- BRKR 0.52
- Revenue
- MDGL $515,547,000.00
- BRKR $3,442,800,000.00
- Revenue This Year
- MDGL $394.12
- BRKR $4.44
- Revenue Next Year
- MDGL $57.74
- BRKR $1.71
- P/E Ratio
- MDGL N/A
- BRKR $63.98
- Revenue Growth
- MDGL 3421.98
- BRKR 10.36
- 52 Week Low
- MDGL $200.63
- BRKR $28.53
- 52 Week High
- MDGL $457.16
- BRKR $72.94
- Technical
- Relative Strength Index (RSI)
- MDGL 62.88
- BRKR 50.90
- Support Level
- MDGL $415.53
- BRKR $30.31
- Resistance Level
- MDGL $440.90
- BRKR $34.44
- Average True Range (ATR)
- MDGL 14.27
- BRKR 1.48
- MACD
- MDGL -4.71
- BRKR 0.38
- Stochastic Oscillator
- MDGL 60.58
- BRKR 80.20
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.